BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) (FRA:NPAT), which is beginning clinical trials of AP-003 as a COVID-19 inhalation therapeutic, announced Wednesday it has selected Florence Healthcare to provide its electronic Trial Master File (eTMF) for the conduct of the trial.
In a statement, BetterLife said the Florence platform will simplify and accelerate forthcoming clinical trials by streamlining internal operations and enabling direct remote connections to the company’s research sites and partners across three countries.
“The complexities of ensuring the accuracy and compliance of study data and documents cannot be overestimated,” said BetterLife CEO Dr Ahmad Doroudian.
READ: BetterLife Pharma to conduct telemedicine coronavirus trials of AP-003 to ease access for patients
“The eTMF is mission critical for us: Deploying Florence’s eTMF for our AP-003 COVID-19 clinical trials has the potential to shorten the time it takes to bring a safe and effective treatment to the market. With the current global increases in cases and corresponding lockdowns, the need for speed is greater than ever,’’ Doroudian added.
Florence VP of Revenue Jeff Pool said that “working with an innovative tech-savvy pharma company like BetterLife aligns with our mission of advancing cures through technology.”
Pool added: “Their need to have an eTMF that is intuitive to use for both their internal teams and their research sites directly reflects our core tenant of building solutions that focus on end-user needs.”
BetterLife said remote site access and connectivity is now a priority for companies looking to start trials in response to rapid industry shifts due to COVID-19 restricting on-site monitoring.
The company said the Florence eTMF is connected to an existing network of 8,000 study sites in 27 countries using its Florence eBinders platform as their Electronic Investigator Site File and supports the rapid implementation of new study sites.
Contact the author: email@example.com
Follow him on Twitter @PatrickMGraham